ZEALLogistics Solution Provider
Zealand Pharma A/S — Profit & Loss Statement
₹59.50
+0.00%
Zealand Pharma A/S Profit & Loss Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.48 Cr | -0.44 Cr |
| Tax Rate For Calcs | 0.26 | 0.26 | 0.26 | 0.26 |
| Normalized EBITDA | 20.77 Cr | 15.36 Cr | 9.27 Cr | 4.38 Cr |
| Total Unusual Items | 0.00 | 0.00 | -1.82 Cr | -1.69 Cr |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -1.82 Cr | -1.69 Cr |
| Net Income From Continuing Operation Net Minority Interest | 12.02 Cr | 9.85 Cr | 5.24 Cr | 1.70 Cr |
| Reconciled Depreciation | 3.13 Cr | 0.91 Cr | 0.25 Cr | 0.18 Cr |
| Reconciled Cost Of Revenue | 172.83 Cr | 93.41 Cr | 107.09 Cr | 54.52 Cr |
| EBITDA | 20.77 Cr | 15.36 Cr | 7.45 Cr | 2.69 Cr |
| EBIT | 17.64 Cr | 14.45 Cr | 7.20 Cr | 2.50 Cr |
| Net Interest Income | -1.87 Cr | -1.22 Cr | 54000.00 | -0.01 Cr |
| Interest Expense | 1.87 Cr | 1.22 Cr | 0.08 Cr | 0.22 Cr |
| Normalized Income | 12.02 Cr | 9.85 Cr | 6.58 Cr | 2.95 Cr |
| Net Income From Continuing And Discontinued Operation | 12.02 Cr | 9.85 Cr | 5.24 Cr | 1.70 Cr |
| Total Expenses | 177.76 Cr | 98.25 Cr | 111.87 Cr | 56.23 Cr |
| Diluted NI Availto Com Stockholders | 12.02 Cr | 9.85 Cr | 7.22 Cr | 1.88 Cr |
| Net Income Common Stockholders | 12.02 Cr | 9.85 Cr | 7.22 Cr | 1.88 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 12.02 Cr | 9.85 Cr | 7.22 Cr | 1.88 Cr |
| Net Income Including Noncontrolling Interests | 12.02 Cr | 9.85 Cr | 7.22 Cr | 1.88 Cr |
| Net Income Discontinuous Operations | 0.00 | 0.00 | — | — |
| Net Income Continuous Operations | 12.02 Cr | 9.85 Cr | 5.24 Cr | 1.70 Cr |
| Tax Provision | 4.10 Cr | 3.47 Cr | 1.88 Cr | 0.59 Cr |
| Pretax Income | 15.77 Cr | 13.23 Cr | 7.12 Cr | 2.29 Cr |
| Other Non Operating Income Expenses | 2.31 Cr | 0.49 Cr | — | — |
| Special Income Charges | 0.00 | 0.00 | -1.82 Cr | -1.69 Cr |
| Net Non Operating Interest Income Expense | -1.87 Cr | -1.22 Cr | 54000.00 | -0.01 Cr |
| Interest Expense Non Operating | 1.87 Cr | 1.22 Cr | 0.08 Cr | 0.22 Cr |
| Operating Income | 15.32 Cr | 13.96 Cr | 9.22 Cr | 4.35 Cr |
| Operating Expense | 4.94 Cr | 4.84 Cr | 4.78 Cr | 1.72 Cr |
| Other Operating Expenses | 4.94 Cr | 4.84 Cr | 2.83 Cr | 0.89 Cr |
| Gross Profit | 20.26 Cr | 18.79 Cr | 14.00 Cr | 6.07 Cr |
| Cost Of Revenue | 172.83 Cr | 93.41 Cr | 107.09 Cr | 54.52 Cr |
| Total Revenue | 193.09 Cr | 112.21 Cr | 121.09 Cr | 60.59 Cr |
| Operating Revenue | 193.09 Cr | 112.21 Cr | 121.09 Cr | 60.59 Cr |
| Diluted Average Shares | — | 1.33 Cr | 1.33 Cr | 1.33 Cr |
| Basic Average Shares | — | 1.33 Cr | 1.33 Cr | 1.33 Cr |
| Diluted EPS | — | 7.40 | 5.43 | 1.41 |
| Basic EPS | — | 7.40 | 5.43 | 1.41 |
| Interest Income | — | — | 0.18 Cr | 0.28 Cr |
| Rent Expense Supplemental | — | — | 0.34 Cr | 0.17 Cr |
| Net Income Extraordinary | — | — | 1.98 Cr | 0.19 Cr |
| Write Off | — | — | 1.82 Cr | 1.77 Cr |
| Total Other Finance Cost | — | — | 0.09 Cr | 0.08 Cr |
| Interest Income Non Operating | — | — | 0.18 Cr | 0.28 Cr |
| Depreciation And Amortization In Income Statement | — | — | 0.25 Cr | 0.18 Cr |
| Amortization | — | — | 35000.00 | 95000.00 |
| Depreciation Income Statement | — | — | 0.25 Cr | 0.17 Cr |
| Selling General And Administration | — | — | 1.36 Cr | 0.48 Cr |
| Selling And Marketing Expense | — | — | 1.15 Cr | 0.36 Cr |
| General And Administrative Expense | — | — | 0.21 Cr | 0.12 Cr |
| Rent And Landing Fees | — | — | 0.34 Cr | 0.17 Cr |
| Other Special Charges | — | — | — | -0.08 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Zealand Pharma A/S
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.